• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    4/1/25 5:00:19 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email
    false 0001979414 0001979414 2025-03-31 2025-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported):

    March 31, 2025

     

    NEONC TECHNOLOGIES HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

     

    001-42567   92-1954864
    (Commission File Number)   (IRS Employer Identification No.)

     

    2 Dole Drive, Westlake Village, CA   91362
    (Address of Principal Executive Offices)   (Zip Code)

     

    (310) 663-7831

    (Registrant’s Telephone Number, Including Area Code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Stock, par value $0.0001   NTHI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01Changes in Registrant’s Certifying Accountant.

     

    On March 31, 2025, NeOnc Technologies Holdings, Inc. (the “Company”) the Company was notified by Marcum LLP (“Marcum”) that Marcum resigned as the independent registered accounting firm of the Company. On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum. On March 31, 2025, Marcum resigned as auditors of the Company and with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ was engaged, effective April 1, 2025, as the Company’s independent registered public accounting firm for the year ended December 31, 2025.

     

    The reports of Marcum regarding the Company’s financial statements for the fiscal years ended December 31, 2024 and December 31, 2023, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except for an explanatory paragraph regarding the Company's ability to continue as a going concern.

     

    During the fiscal years ended December 31, 2024 and December 31, 2023, and through March 31, 2025, the date of Marcum’s resignation, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to such disagreement in its report and (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), other than the material weaknesses in internal controls identified by management as of December 31, 2024 related to a) lack of proper segregation of duties; b) lack of sufficient entity level controls; c) lack of sufficient controls of significant transaction classes; d) lack of sufficient controls over related party transactions; and e) lack of sufficient information technology general controls.

     

    During the fiscal years ended December 31, 2024 and December 31, 2023, and through April 1, 2025, neither the Company nor anyone on the Company’s behalf consulted with CBIZ regarding (i) the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ on the Company’s financial statements, and CBIZ did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any such accounting, auditing, or financial reporting issue or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions), as that term is described in Item 304(a)(1)(iv) of Regulation S-K, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.

     

    The Company provided Marcum with a copy of this Current Report on Form 8-K prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”) and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of Marcum’s letter, dated April 1, 2025, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits

     

    16.1   Letter from Marcum dated April 1, 2025
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: April 1, 2025 NeOnc Technologies Holdings, Inc.
         
      By: /s/ Dr. Thomas Chen
        Name: Dr. Thomas Chen
        Title: Chief Executive Officer

     

    2

    Get the next $NTHI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Garnett Keithly bought $976 worth of shares (135 units at $7.23), increasing direct ownership by 0.06% to 240,225 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:55:49 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO Garnett Keithly bought $631 worth of shares (90 units at $7.01), increasing direct ownership by 0.04% to 240,090 units (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:54:01 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Delshad Jim bought $37,258 worth of shares (5,100 units at $7.31), increasing direct ownership by 10% to 55,310 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/19/25 9:27:02 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Garnett Keithly bought $976 worth of shares (135 units at $7.23), increasing direct ownership by 0.06% to 240,225 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:55:49 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO Garnett Keithly bought $631 worth of shares (90 units at $7.01), increasing direct ownership by 0.04% to 240,090 units (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:54:01 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Delshad Jim bought $37,258 worth of shares (5,100 units at $7.31), increasing direct ownership by 10% to 55,310 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/19/25 9:27:02 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    SEC Filings

    See more

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.

      10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      5/9/25 5:00:30 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.

      EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      5/7/25 12:15:13 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.

      424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      5/6/25 5:07:31 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

      -- 176 Patents Issued and Outstanding Reinforces NeOnc's Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company's IP portfolio, covering its core pipeline, currently comprises 126 issued patents - 29 in the United States and 97 internationally; and 50 pending patents - 19 in the United States and 31 internationally. NeOnc's expanding IP portfolio reflects its innovation engine as well as its comm

      4/15/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

      -- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial's 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive me

      4/14/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

      CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives. "Amir's appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs," said Dr. Thomas Chen, CEO of NeOnc. "His e

      4/10/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care